Current Opinion

American Journal of Clinical Dermatology

, Volume 7, Issue 1, pp 7-12

First online:

Topical Macrolide Immunomodulators

A Role in the Treatment of Vitiligo?
  • Milan TjioeAffiliated withDepartment of Dermatology, Radboud University Nijmegen Medical Centre Email author 
  • , Wynand H.P.M. VissersAffiliated withDepartment of Dermatology, Radboud University Nijmegen Medical Centre
  • , Marie-Jeanne P. Gerritsen

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Recently, topical macrolide immunomodulators have been successfully introduced in the treatment of atopic dermatitis. With the growing interest in this new line of topical immunosuppressants, research into the efficacy of these medicines in other T-cell-mediated skin diseases, such as psoriasis, lichen planus, and even vitiligo, is expanding rapidly. It is generally accepted that autoimmune factors play an important role in vitiligo. In this article, the possible use and mechanism of topical macrolide immunomodulators in the treatment of vitiligo are discussed, together with the current state of clinical studies and case reports. These limited reports indicate that topical macrolide immunomodulators may play a role in the treatment of vitiligo, particularly in areas where use of potent corticosteroids is contraindicated.